Evidence map›Paper›PMID 24967154›Full record

ArticleFEBS open bio2014

Structural and degradative aspects of ornithine decarboxylase antizyme inhibitor 2.

Bruno Ramos-Molina, Ana Lambertos, Andrés J Lopez-Contreras, Joanna M Kasprzak, Anna Czerwoniec, Janusz M Bujnicki, Asunción Cremades, Rafael Peñafiel

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Bruno Ramos-MolinaDepartment of Biochemistry and Molecular Biology B and Immunology, University of Murcia, Spain ; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
Ana LambertosDepartment of Biochemistry and Molecular Biology B and Immunology, University of Murcia, Spain ; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
Andrés J Lopez-ContrerasGenomic Instability Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Joanna M KasprzakInstitute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Poznan, Poland.
Anna CzerwoniecInstitute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Poznan, Poland.
Janusz M BujnickiInternational Institute of Molecular and Cell Biology, Warsaw, Poland.
Asunción CremadesDepartment of Biochemistry and Molecular Biology B and Immunology, University of Murcia, Spain ; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
Rafael PeñafielDepartment of Biochemistry and Molecular Biology B and Immunology, University of Murcia, Spain ; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
Universidad de Murcia · ESAdam Mickiewicz University in Poznań · PLInstituto Murciano de Investigación Biosanitaria · ESInternational Institute of Molecular and Cell Biology · PLSpanish National Cancer Research Centre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ornithine decarboxylase (ODC) is the key enzyme in the polyamine biosynthetic pathway. ODC levels are controlled by polyamines through the induction of antizymes (AZs), small proteins that inhibit ODC and target it to proteasomal degradation without ubiquitination. Antizyme inhibitors (AZIN1 and AZIN2) are proteins homologous to ODC that bind to AZs and counteract their negative effect on ODC. Whereas ODC and AZIN1 are well-characterized proteins, little is known on the structure and stability of AZIN2, the lastly discovered member of this regulatory circuit. In this work we first analyzed structural aspects of AZIN2 by combining biochemical and computational approaches. We demonstrated that AZIN2, in contrast to ODC, does not form homodimers, although the predicted tertiary structure of the AZIN2 monomer was similar to that of ODC. Furthermore, we identified conserved residues in the antizyme-binding element, whose substitution drastically affected the capacity of AZIN2 to bind AZ1. On the other hand, we also found that AZIN2 is much more labile than ODC, but it is highly stabilized by its binding to AZs. Interestingly, the administration of the proteasome inhibitor MG132 caused differential effects on the three AZ-binding proteins, having no effect on ODC, preventing the degradation of AZIN1, but unexpectedly increasing the degradation of AZIN2. Inhibitors of the lysosomal function partially prevented the effect of MG132 on AZIN2. These results suggest that the degradation of AZIN2 could be also mediated by an alternative route to that of proteasome. These findings provide new relevant information on this unique regulatory mechanism of polyamine metabolism.

Indexed as

AntizymeAntizyme-binding elementAZ, antizymeAZBE, antizyme-binding elementAZIN, antizyme inhibitorERGIC, endoplasmic reticulum-Golgi intermediate compartmentGDT_TS, global distance test total scoreHA, hemagglutininHEK, human embryonic kidneyHomology modelingODC, ornithine decarboxylasePAGE, polyacrylamide gel electrophoresisPolyaminesProteasome inhibitorsProtein degradationRMSD, root-mean-square deviationTGN, trans-Golgi network

Identifiers

PMID24967154
PMCPMC4066113
OpenAlexW2041633926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.